Cargando…
Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study
OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513423/ https://www.ncbi.nlm.nih.gov/pubmed/32967887 http://dx.doi.org/10.1136/bmjopen-2020-041983 |
_version_ | 1783586381216350208 |
---|---|
author | Berzuini, Carlo Hannan, Cathal King, Andrew Vail, Andy O'Leary, Claire Brough, David Galea, James Ogungbenro, Kayode Wright, Megan Pathmanaban, Omar Hulme, Sharon Allan, Stuart Bernardinelli, Luisa Patel, Hiren C |
author_facet | Berzuini, Carlo Hannan, Cathal King, Andrew Vail, Andy O'Leary, Claire Brough, David Galea, James Ogungbenro, Kayode Wright, Megan Pathmanaban, Omar Hulme, Sharon Allan, Stuart Bernardinelli, Luisa Patel, Hiren C |
author_sort | Berzuini, Carlo |
collection | PubMed |
description | OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restricted to baseline predictors and do not always use contemporary statistical methods. We sought to explore the benefits of incorporating dynamic changes in routinely measured biomarkers, non-linear effects and applying ‘state-of-the-art’ statistical methods in the development of a prognostic model to predict death in hospitalised patients with COVID-19. DESIGN: The data were analysed from admissions with COVID-19 to three hospital sites. Exploratory data analysis included a graphical approach to partial correlations. Dynamic biomarkers were considered up to 5 days following admission rather than depending solely on baseline or single time-point data. Marked departures from linear effects of covariates were identified by employing smoothing splines within a generalised additive modelling framework. SETTING: 3 secondary and tertiary level centres in Greater Manchester, the UK. PARTICIPANTS: 392 hospitalised patients with a diagnosis of COVID-19. RESULTS: 392 patients with a COVID-19 diagnosis were identified. Area under the receiver operating characteristic curve increased from 0.73 using admission data alone to 0.75 when also considering results of baseline blood samples and to 0.83 when considering dynamic values of routinely collected markers. There was clear non-linearity in the association of age with patient outcome. CONCLUSIONS: This study shows that clinical prediction models to predict death in hospitalised patients with COVID-19 can be improved by taking into account both non-linear effects in covariates such as age and dynamic changes in values of biomarkers. |
format | Online Article Text |
id | pubmed-7513423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-75134232020-09-25 Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study Berzuini, Carlo Hannan, Cathal King, Andrew Vail, Andy O'Leary, Claire Brough, David Galea, James Ogungbenro, Kayode Wright, Megan Pathmanaban, Omar Hulme, Sharon Allan, Stuart Bernardinelli, Luisa Patel, Hiren C BMJ Open Research Methods OBJECTIVES: Being able to predict which patients with COVID-19 are going to deteriorate is important to help identify patients for clinical and research practice. Clinical prediction models play a critical role in this process, but current models are of limited value because they are typically restricted to baseline predictors and do not always use contemporary statistical methods. We sought to explore the benefits of incorporating dynamic changes in routinely measured biomarkers, non-linear effects and applying ‘state-of-the-art’ statistical methods in the development of a prognostic model to predict death in hospitalised patients with COVID-19. DESIGN: The data were analysed from admissions with COVID-19 to three hospital sites. Exploratory data analysis included a graphical approach to partial correlations. Dynamic biomarkers were considered up to 5 days following admission rather than depending solely on baseline or single time-point data. Marked departures from linear effects of covariates were identified by employing smoothing splines within a generalised additive modelling framework. SETTING: 3 secondary and tertiary level centres in Greater Manchester, the UK. PARTICIPANTS: 392 hospitalised patients with a diagnosis of COVID-19. RESULTS: 392 patients with a COVID-19 diagnosis were identified. Area under the receiver operating characteristic curve increased from 0.73 using admission data alone to 0.75 when also considering results of baseline blood samples and to 0.83 when considering dynamic values of routinely collected markers. There was clear non-linearity in the association of age with patient outcome. CONCLUSIONS: This study shows that clinical prediction models to predict death in hospitalised patients with COVID-19 can be improved by taking into account both non-linear effects in covariates such as age and dynamic changes in values of biomarkers. BMJ Publishing Group 2020-09-23 /pmc/articles/PMC7513423/ /pubmed/32967887 http://dx.doi.org/10.1136/bmjopen-2020-041983 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Methods Berzuini, Carlo Hannan, Cathal King, Andrew Vail, Andy O'Leary, Claire Brough, David Galea, James Ogungbenro, Kayode Wright, Megan Pathmanaban, Omar Hulme, Sharon Allan, Stuart Bernardinelli, Luisa Patel, Hiren C Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title | Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title_full | Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title_fullStr | Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title_full_unstemmed | Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title_short | Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study |
title_sort | value of dynamic clinical and biomarker data for mortality risk prediction in covid-19: a multicentre retrospective cohort study |
topic | Research Methods |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513423/ https://www.ncbi.nlm.nih.gov/pubmed/32967887 http://dx.doi.org/10.1136/bmjopen-2020-041983 |
work_keys_str_mv | AT berzuinicarlo valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT hannancathal valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT kingandrew valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT vailandy valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT olearyclaire valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT broughdavid valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT galeajames valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT ogungbenrokayode valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT wrightmegan valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT pathmanabanomar valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT hulmesharon valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT allanstuart valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT bernardinelliluisa valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy AT patelhirenc valueofdynamicclinicalandbiomarkerdataformortalityriskpredictionincovid19amulticentreretrospectivecohortstudy |